Table 3.

Take-Home Points for COVID-19 Vaccination in Patients With IBD

Patients with IBD, including those on advanced therapies, are not at increased risk of SARS-CoV-2 infection.

Systemic corticosteroids portend an increased risk of severe COVID-19, whereas other medications, including advanced therapies (ie, anti-TNFs, non–anti-TNF biologics, and JAK inhibitors), do not.

There has not been published data to suggest that COVID-19 infection alters IBD activity.

Vaccination is safe in patients with IBD and does not affect disease activity; the side effect profile is similar to that of the general population.

Vaccination decreases rates of COVID-19 infection and infection-related complications with similar efficacy to those observed in patients without IBD.

Adult patients with IBD who have previously completed the original primary vaccine series should receive a dose of the updated 2023-2024 COVID-19 vaccine.

IBD, inflammatory bowel disease; JAK, Janus kinase; TNF, tumor necrosis factor.